MX2018015599A - Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer. - Google Patents
Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer.Info
- Publication number
- MX2018015599A MX2018015599A MX2018015599A MX2018015599A MX2018015599A MX 2018015599 A MX2018015599 A MX 2018015599A MX 2018015599 A MX2018015599 A MX 2018015599A MX 2018015599 A MX2018015599 A MX 2018015599A MX 2018015599 A MX2018015599 A MX 2018015599A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion protein
- sequence
- respect
- enveloped virus
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
- C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504120P | 2017-05-10 | 2017-05-10 | |
| PCT/US2018/032018 WO2018209052A1 (en) | 2017-05-10 | 2018-05-10 | Enveloped virus resistant to complement inactivation for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018015599A true MX2018015599A (es) | 2019-05-16 |
Family
ID=64105722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015599A MX2018015599A (es) | 2017-05-10 | 2018-05-10 | Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11274141B2 (enExample) |
| EP (1) | EP3621635A4 (enExample) |
| JP (1) | JP7161940B2 (enExample) |
| KR (3) | KR20250118857A (enExample) |
| CN (1) | CN109414483B (enExample) |
| AU (1) | AU2018265258B2 (enExample) |
| BR (1) | BR112018075281A2 (enExample) |
| CA (1) | CA3026892A1 (enExample) |
| IL (1) | IL263979B2 (enExample) |
| MX (1) | MX2018015599A (enExample) |
| WO (1) | WO2018209052A1 (enExample) |
| ZA (1) | ZA201808040B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN112759654A (zh) * | 2019-11-06 | 2021-05-07 | 深圳普菲科生命科技有限公司 | 一种病毒囊膜蛋白装配系统及其方法和应用 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| AU2022227480A1 (en) * | 2021-02-26 | 2023-09-14 | Sillajen, Inc. | Oncolytic virus and use thereof |
| CN113736810B (zh) * | 2021-09-08 | 2024-05-24 | 苏州因特药物研发有限公司 | 构建体、载体、蛋白、细胞、制备方法、产品及应用 |
| KR20240003051A (ko) * | 2022-06-29 | 2024-01-08 | 신라젠(주) | Cd55 및 cd59를 동시 발현하는 항암 바이러스 |
| AU2023338427A1 (en) * | 2022-09-07 | 2025-04-03 | Sillajen, Inc. | Novel use of oncolytic virus |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374548A (en) * | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| PT1486211E (pt) | 1993-04-30 | 2009-02-02 | Wellstat Biologics Corp | Composições para tratamento do cancro utilizando vírus |
| JPH10313865A (ja) * | 1997-05-15 | 1998-12-02 | Deinabetsuku Kenkyusho:Kk | ヒト補体制御因子が呈示されたベクター |
| EP1030928A1 (en) | 1997-11-21 | 2000-08-30 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Development of viruses resistant to inactivation by the human complement system |
| AP1968A (en) | 1997-12-22 | 2009-04-30 | Univ Tennessee Res Corp | Recombinant rhabdovirus containing a heterologous fusion protein. |
| EP1071705A2 (en) * | 1998-04-02 | 2001-01-31 | Rigel Pharmaceuticals, Inc. | Peptides causing formation of compact structures |
| AU4246900A (en) | 1999-04-15 | 2000-11-02 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| EP2292259A3 (en) * | 2002-11-15 | 2011-03-23 | MUSC Foundation For Research Development | Complement receptor 2 targeted complement modulators |
| EP1784506B1 (en) | 2004-07-21 | 2010-08-25 | Dana-Farber Cancer Institute, Inc. | Lentiviral vectors and uses thereof |
| JP5050198B2 (ja) | 2006-09-05 | 2012-10-17 | 国立大学法人大阪大学 | ヒト補体制御因子発現遺伝子およびその利用 |
| WO2008118258A2 (en) * | 2007-02-06 | 2008-10-02 | Genizon Biosciences Inc. | Genemap of the human genes associated with adhd |
| KR20090122465A (ko) * | 2007-03-01 | 2009-11-30 | 어드벤스드 비젼 테라피스, 인코포레이티드 | 염증성 질환의 치료 |
| US8877896B2 (en) | 2008-02-15 | 2014-11-04 | Tufts University | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders |
| JP2014516517A (ja) | 2011-04-29 | 2014-07-17 | キージーン・エン・フェー | グリホサート耐性強化 |
| CA2833931C (en) | 2011-05-05 | 2021-05-04 | Wellstat Immunotherapeutics, Llc | Complement factor b analogs and their uses |
| CN110078831A (zh) * | 2011-12-01 | 2019-08-02 | 圆祥生命科技股份有限公司 | 补体和vegf途径的蛋白质抑制剂及其使用方法 |
| FI3888674T3 (fi) * | 2014-04-07 | 2024-07-02 | Novartis Ag | Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| RS61907B1 (sr) * | 2015-04-06 | 2021-06-30 | Subdomain Llc | Polipeptidi koji sadrže de novo vezujući domen i njihova primena |
| GB201507119D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| CN107708741A (zh) | 2015-06-12 | 2018-02-16 | 免疫医疗公司 | 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法 |
| EP3458576A4 (en) | 2016-05-19 | 2020-03-25 | Turnstone Limited Partnership | PSEUDOTYPIZED ONCOLYTIC RHABDOVIRUS AND THEIR USE IN COMBINATION THERAPY |
-
2018
- 2018-05-10 CA CA3026892A patent/CA3026892A1/en active Pending
- 2018-05-10 BR BR112018075281-9A patent/BR112018075281A2/pt unknown
- 2018-05-10 IL IL263979A patent/IL263979B2/en unknown
- 2018-05-10 WO PCT/US2018/032018 patent/WO2018209052A1/en not_active Ceased
- 2018-05-10 EP EP18798575.9A patent/EP3621635A4/en active Pending
- 2018-05-10 AU AU2018265258A patent/AU2018265258B2/en active Active
- 2018-05-10 MX MX2018015599A patent/MX2018015599A/es unknown
- 2018-05-10 KR KR1020257024807A patent/KR20250118857A/ko active Pending
- 2018-05-10 KR KR1020187037869A patent/KR102662049B1/ko active Active
- 2018-05-10 KR KR1020247013722A patent/KR102839445B1/ko active Active
- 2018-05-10 US US16/303,729 patent/US11274141B2/en active Active
- 2018-05-10 CN CN201880002553.7A patent/CN109414483B/zh active Active
- 2018-05-10 JP JP2018564966A patent/JP7161940B2/ja active Active
- 2018-11-28 ZA ZA2018/08040A patent/ZA201808040B/en unknown
-
2022
- 2022-02-18 US US17/674,990 patent/US20220169701A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220169701A1 (en) | 2022-06-02 |
| BR112018075281A2 (pt) | 2020-02-11 |
| RU2018146446A (ru) | 2021-06-10 |
| AU2018265258A1 (en) | 2019-01-17 |
| KR102839445B1 (ko) | 2025-07-28 |
| IL263979B1 (en) | 2023-05-01 |
| IL263979A (en) | 2019-02-28 |
| IL263979B2 (en) | 2023-09-01 |
| KR20250118857A (ko) | 2025-08-06 |
| KR102662049B1 (ko) | 2024-05-23 |
| JP7161940B2 (ja) | 2022-10-27 |
| ZA201808040B (en) | 2019-09-25 |
| US20190194292A1 (en) | 2019-06-27 |
| EP3621635A1 (en) | 2020-03-18 |
| CA3026892A1 (en) | 2018-11-15 |
| EP3621635A4 (en) | 2021-02-24 |
| RU2018146446A3 (enExample) | 2021-09-10 |
| US11274141B2 (en) | 2022-03-15 |
| KR20200005721A (ko) | 2020-01-16 |
| CN109414483B (zh) | 2025-10-24 |
| AU2018265258B2 (en) | 2023-01-05 |
| KR20240073085A (ko) | 2024-05-24 |
| WO2018209052A1 (en) | 2018-11-15 |
| CN109414483A (zh) | 2019-03-01 |
| JP2020519230A (ja) | 2020-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018015599A (es) | Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer. | |
| AR122964A2 (es) | Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
| CO2018005306A2 (es) | Variantes del factor viii reducido con cpg, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasia | |
| CO2017010831A2 (es) | Adenovirus oncolítico que codifica una proteína b7 | |
| PE20181338A1 (es) | Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden | |
| MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
| CL2017001070A1 (es) | Variantes de interferon a2b | |
| MX380658B (es) | Variantes de region fc con union mejorada de la proteina a. | |
| UY36304A (es) | Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes | |
| MX2019003886A (es) | Receptores de antigenos quimericos para el tratamiento del cancer. | |
| EA202091342A3 (ru) | Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения | |
| MX395275B (es) | Construcciones con un dominio sirp-alfa o sus variantes | |
| MX2017011847A (es) | Modulación de inmunidad tumoral por liberación de o2 mediada por proteína. | |
| MX2017008449A (es) | Polipeptido de pirina y modulacion inmune. | |
| MX2020010075A (es) | Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
| PE20191786A1 (es) | Anticuerpo monoclonal para pd-l1 | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| MX2017010359A (es) | Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). | |
| PE20190966A1 (es) | Factor viii direccionado a los globulos rojos y metodo para su uso | |
| AR132574A2 (es) | UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA | |
| MX2017011732A (es) | Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos. | |
| MX2018002616A (es) | Proteina de fusion. | |
| BR112017005338A2 (pt) | composição contendo glicosaminoglicanos e proteínas |